These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37971871)

  • 1. TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies.
    Pierce KK; Durbin AP; Walsh MR; Carmolli M; Sabundayo BP; Dickson DM; Diehl SA; Whitehead SS; Kirkpatrick BD
    J Clin Invest; 2024 Feb; 134(3):. PubMed ID: 37971871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial.
    Walsh MR; Alam MS; Pierce KK; Carmolli M; Alam M; Dickson DM; Bak DM; Afreen S; Nazib F; Golam K; Qadri F; Diehl SA; Durbin AP; Whitehead SS; Haque R; Kirkpatrick BD
    Lancet Infect Dis; 2024 Feb; 24(2):150-160. PubMed ID: 37776876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled human infection study underpins efficacy of the tetravalent live-attenuated dengue vaccine TV005.
    Wilder-Smith A
    J Clin Invest; 2024 Feb; 134(3):. PubMed ID: 38299597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.
    Kirkpatrick BD; Durbin AP; Pierce KK; Carmolli MP; Tibery CM; Grier PL; Hynes N; Diehl SA; Elwood D; Jarvis AP; Sabundayo BP; Lyon CE; Larsson CJ; Jo M; Lovchik JM; Luke CJ; Walsh MC; Fraser EA; Subbarao K; Whitehead SS
    J Infect Dis; 2015 Sep; 212(5):702-10. PubMed ID: 25801652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.
    Kirkpatrick BD; Whitehead SS; Pierce KK; Tibery CM; Grier PL; Hynes NA; Larsson CJ; Sabundayo BP; Talaat KR; Janiak A; Carmolli MP; Luke CJ; Diehl SA; Durbin AP
    Sci Transl Med; 2016 Mar; 8(330):330ra36. PubMed ID: 27089205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults.
    Russell KL; Rupp RE; Morales-Ramirez JO; Diaz-Perez C; Andrews CP; Lee AW; Finn TS; Cox KS; Falk Russell A; Schaller MM; Martin JC; Hyatt DM; Gozlan-Kelner S; Bili A; Coller BG
    Hum Vaccin Immunother; 2022 Nov; 18(5):2046960. PubMed ID: 35290152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults.
    Gunale B; Farinola N; Yeolekar L; Shrivastava S; Girgis H; Poonawalla CS; Dhere RM; Arankalle V; Chandra Mishra A; Mehla R; Kulkarni PS
    Vaccine; 2023 Aug; 41(38):5614-5621. PubMed ID: 37532611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.
    Osorio JE; Velez ID; Thomson C; Lopez L; Jimenez A; Haller AA; Silengo S; Scott J; Boroughs KL; Stovall JL; Luy BE; Arguello J; Beatty ME; Santangelo J; Gordon GS; Huang CY; Stinchcomb DT
    Lancet Infect Dis; 2014 Sep; 14(9):830-8. PubMed ID: 25087476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.
    George SL; Wong MA; Dube TJ; Boroughs KL; Stovall JL; Luy BE; Haller AA; Osorio JE; Eggemeyer LM; Irby-Moore S; Frey SE; Huang CY; Stinchcomb DT
    J Infect Dis; 2015 Oct; 212(7):1032-41. PubMed ID: 25791116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
    Biswal S; Borja-Tabora C; Martinez Vargas L; Velásquez H; Theresa Alera M; Sierra V; Johana Rodriguez-Arenales E; Yu D; Wickramasinghe VP; Duarte Moreira E; Fernando AD; Gunasekera D; Kosalaraksa P; Espinoza F; López-Medina E; Bravo L; Tuboi S; Hutagalung Y; Garbes P; Escudero I; Rauscher M; Bizjajeva S; LeFevre I; Borkowski A; Saez-Llorens X; Wallace D;
    Lancet; 2020 May; 395(10234):1423-1433. PubMed ID: 32197105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A heterologous prime-boost strategy for immunization against Dengue virus combining the Tetra DIIIC subunit vaccine candidate with the TV005 live-attenuated tetravalent vaccine.
    Valdés I; Izquierdo A; Cobas K; Thao P; Anh Duc H; Duc Loc H; Dung LT; Lazo L; Suzarte E; Pérez Y; Romero Y; Yaugel M; Marcos E; Guzmán MG; Dat DT; Hien ND; Guillén G; Gil L; Hermida L
    J Gen Virol; 2019 Jun; 100(6):975-984. PubMed ID: 31090533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles.
    Lindow JC; Durbin AP; Whitehead SS; Pierce KK; Carmolli MP; Kirkpatrick BD
    Vaccine; 2013 Jul; 31(33):3347-52. PubMed ID: 23735680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?
    Whitehead SS
    Expert Rev Vaccines; 2016; 15(4):509-17. PubMed ID: 26559731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine.
    Odio CD; Lowman KE; Law M; Aogo RA; Hunsberger S; Wood BJ; Kassin M; Levy E; Callier V; Firdous S; Hasund CM; Voirin C; Kattappuram R; Yek C; Manning J; Durbin A; Whitehead SS; Katzelnick LC
    BMC Infect Dis; 2023 May; 23(1):345. PubMed ID: 37221466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
    Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
    Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding.
    Torresi J; Richmond PC; Heron LG; Qiao M; Marjason J; Starr-Spires L; van der Vliet D; Jin J; Wartel TA; Bouckenooghe A
    J Infect Dis; 2017 Oct; 216(7):834-841. PubMed ID: 28968794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human CD4
    Angelo MA; Grifoni A; O'Rourke PH; Sidney J; Paul S; Peters B; de Silva AD; Phillips E; Mallal S; Diehl SA; Kirkpatrick BD; Whitehead SS; Durbin AP; Sette A; Weiskopf D
    J Virol; 2017 Mar; 91(5):. PubMed ID: 27974563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.
    Barban V; Mantel N; De Montfort A; Pagnon A; Pradezynski F; Lang J; Boudet F
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.